What is Vertex?
Founded in 1989 and headquartered in Boston, Massachusetts, Vertex Pharmaceuticals is a prominent player in the biotechnology sector. The company dedicates its resources to the discovery, development, and commercialization of innovative therapies aimed at addressing a wide spectrum of serious diseases. Vertex's strategic focus on unmet medical needs positions it as a key innovator within the life sciences industry, leveraging scientific advancements to create impactful treatments.
How much funding has Vertex raised?
Vertex has raised a total of $2.5B across 11 funding rounds:
Stock Offering
$25M
Debt
$153M
Grant
$21M
Stock Offering
$175.7M
Stock Offering
$300.3M
Multiple Rounds
$616.9M
Stock Offering
$313.3M
Stock Offering
$488.1M
Debt
$400M
Stock Issuance/Offering (1999): $25M with participation from Undisclosed
Debt (2004): $153M led by Undisclosed
Grant (2004): $21M supported by Cystic Fibrosis Foundation Therapeutics Inc.
Stock Issuance/Offering (2005): $175.7M featuring Undisclosed
Stock Issuance/Offering (2006): $300.3M backed by Undisclosed
Stock Issuance/Offering (2008): $112.1M with participation from Undisclosed
Debt (2008): $287.5M led by Undisclosed
Stock Issuance/Offering (2008): $217.3M supported by Undisclosed
Stock Issuance/Offering (2009): $313.3M featuring Undisclosed
Stock Issuance/Offering (2009): $488.1M backed by Undisclosed
Debt (2010): $400M with participation from Undisclosed
Key Investors in Vertex
Cystic Fibrosis Foundation Therapeutics Inc.
Cystic Fibrosis Foundation Therapeutics Inc. is an organization focused on funding research and development for cystic fibrosis treatments, indicating a strategic interest in therapeutic advancements for genetic diseases.
Undisclosed Investors
Undisclosed Investors
What's next for Vertex?
The substantial enterprise-level funding and recent strategic investment signal Vertex's robust financial standing and its commitment to advancing its pipeline. This capital infusion is anticipated to accelerate the company's research and development initiatives, potentially leading to the advancement of novel drug candidates through clinical trials and towards market approval. Vertex's ongoing pursuit of breakthroughs in disease treatment suggests a future focused on expanding its therapeutic portfolio and solidifying its market leadership.
See full Vertex company page
